Background

The family of inhibitor of differentiation/DNA binding (Id) proteins is known to regulate development in several tissues. One member of this gene family, Id-1, has been implicated in mammary development and carcinogenesis. Mammary glands contain various cell types, among which the luminal epithelial cells are primarily targeted for proliferation, differentiation and carcinogenesis. Therefore, to assess the precise significance of Id-1 in mammary biology and carcinogenesis, we examined its cellular localization in vivo using immunohistochemistry.

Methods

Extracts of whole mammary glands from wild type and Id-1 null mutant mice, and tissue sections from paraffin-embedded mouse mammary glands from various developmental stages and normal human breast were subjected to immunoblot and immunohistochemical analyses, respectively. In both these procedures, an anti-Id-1 rabbit polyclonal antibody was used for detection of Id-1.

Results

In immunoblot analyses, using whole mammary gland extracts, Id-1 was detected. In immunohistochemical analyses, however, Id-1 was not detected in the luminal epithelial cells of mammary glands during any stage of development, but it was detected in vascular endothelial cells.

Conclusion

Id-1 is not expressed in the luminal epithelial cells of mammary glands.

Inhibitor of differentiation/DNA binding (Id) proteins belong to a subfamily of helix–loop–helix (HLH) proteins. Four mammalian members of this family (Id1-Id4) have been identified. The distinguishing characteristic of Id proteins is that, unlike the basic HLH proteins, they do not contain a basic DNA binding domain. Nevertheless, they can regulate cell functions primarily by dimerization with other transcriptional regulators, principally basic HLH proteins.

There is extensive documentation that Id proteins promote cell proliferation and negatively regulate differentiation. High levels of Id gene expression have also been observed in tumor cell lines derived from different tissues [1, 2]. In accordance with this, one of the members of this gene family (Id-1) has been shown to promote proliferation and to inhibit functional differentiation of mouse mammary epithelial cells (SCp2 cells), maintained in cell culture [3].

The normal mammary gland is composed of several cell types, but it is the luminal epithelial cells lining the inside of the ducts and the lobules that are primarily targeted for proliferation, differentiation and carcinogenesis. Therefore, to assess the precise significance of any regulatory factor in mammary biology and its significance to carcinogenesis, it is essential to examine its cellular localization in vivo. This is particularly important in the case of ubiquitously expressed proteins, such as Ids. Accordingly, in the present study we examined the in situ localization of Id-1 in normal mammary glands, and we report that Id-1 is not expressed in the luminal epithelial cells.

The source of mammary tissues, FVB and BALB/c strains of mice, used for developmental studies were as follows: pubertal (6 weeks old), adult nulliparous (12 weeks old), early pregnant (6 days gestation), lactating (day 7, postpartum), and postlactational involution (3 days after pup removal). Id-1 null mutant mice (129Sv/C57BL) have been described previously [4]. For these null mutant mice, the corresponding strain of wild type mice was used as a control. The mice were housed and cared for in accordance with the National Institutes of Health guide to humane use of animals in research.

Analysis for in situlocalization of Id-1

For immunohistochemistry, tissue sections were deparaffinized, rehydrated, and soaked in antigen unmasking solution (Vector, Burlingame, CA, USA), The sections were then heated in the microwave oven for 21 min to reveal antigens. The sections were incubated with Immuno Pure Peroxidase Suppressor (Pierce, Rockford, IL, USA) to quench the endogenous peroxidase for 1 hour. The Biotin/Avidin blocking kit (Vector) was then used to block the nonspecific background. The antigen–antibody complexes were identified using the Universal DAKO LSAB2-labeled streptavidin–biotin peroxidase kit (DAKO, Carpinteria, CA, USA). The sections were counterstained with Mayer's hematoxylin solution (DAKO).

Validation of the antibody

The Id-1 antibody used in the present studies (C-20) was the same as that used previously in immunoblot analyses for demonstrating Id-1 expression in various tissue/cell extracts, including mammary cells [3, 5–8]. As shown in Figure 1, in immunoblot analyses of whole mammary gland extracts of wild type mice (lanes 1 and 3 corresponding to 129Sv/C57BL and FVB, respectively), two immunoreactive bands were detected in the region of 15–20 kDa. Among these, the top band was absent in extracts prepared from mammary glands of Id-1 null mutant mice (Fig. 1, lane 2), indicating that it corresponded to Id-1. In contrast, in extracts of wild type mouse testis, as reported previously [5], a single immunoreactive band was detected (Fig. 1, lane 4) and this corresponded to the top band in mammary extracts. Similarly, only the top band was detected in extracts of wild type mouse uterus and intestine (Fig. 1, lanes 5 and 6, respectively). Both the top and the bottom bands, detected in mammary extracts of wild type mice, were absent when blots were incubated with Id-1 antibody in the presence of the peptide used for generation of the antibody (Fig. 1, lane 7). These bands were also absent with the deletion of the primary antibody (data not shown). These observations thus confirmed that the C-20 antibody was capable of detecting Id-1, and also demonstrated its presence in whole mammary gland extracts.

Figure 1

Immunoblot analyses for Id-1 in various mouse tissues. Lysates were prepared from various mouse tissues and analyzed for Id-1, using C-20 antibody, as described in the text. The positions of the molecular weight standards (kDa) are shown on the right. Lanes 1 and 3, wild type mammary glands (129Sv/C57BL and FVB, respectively); lane 2, mammary glands from Id-1 null mutant mouse; lanes 4–6, testis, uterus and intestine from wild type mice, respectively; lane 7, mammary gland extract of wild type mice in which treatment with the primary antibody was performed in the presence of the blocking peptide.

The C-20 antibody is known to detect Id-1 in paraffin-embedded tissue sections and has been used successfully for the analyses of Id-1 in sertoli cells of testis by immunohistochemistry [5]. Nevertheless, we verified the ability of the C-20 antibody to detect Id-1, with fidelity, in immunohistochemical analyses. To achieve this we analyzed the vasculature of the developing brain, since Id-1 gene expression has been demonstrated previously in this tissue, by in situ hybridization [9]. Immunoreactivity was detected in the nuclei of the vasculature of the developing brain, as shown in Figure 2A,2B, and the pattern of immunostaining was similar to that observed for Id-1 gene expression.

Figure 2

Immunohistochemical analyses for Id-1. (A), (B) The immunoreactivity in the vasculature (arrows) of the developing brain (inset, B) at day 12.5 of gestation. Original magnification, (A) 50 ×, (B) 400 ×.

Id-1 is not detectable in luminal epithelial cells of mammary glands

We next examined the in situ localization of Id-1 in mammary glands. As shown in Figure 3A, immunoreactivity was not detected either in the luminal epithelial cells or in the stroma of mammary glands of adult nulliparous females. Immunoreactivity was detected, however, in the cytoplasm of myoepithelial cells, and this was completely abolished in the presence of the blocking peptide used for the generation of Id-1 (C-20) antibody (Fig. 3B). Nevertheless, the staining observed in the myoepithelial cells did not appear to be specific to Id-1 since it was also present in mammary myoepithelial cells of Id-1 null mutant mice (compare Fig. 3D and 3E). Similar to mouse mammary glands, Id-1 immunoreactivity was also not observed in luminal epithelial cells of normal human mammary glands, but was detected in the myoepithelial cells (Fig. 3C).

The fact that Id-1 could be detected in mouse mammary tissue extracts by immunoblot analyses but was undetectable in mammary cells by immunohistochemical analyses led us to consider that the Id-1 detected in tissue extracts might have been derived from nonmammary cells. A potential source was vascular endothelial cells since Id-1 is also expressed in the blood vessels outside the central nervous system [9]. Immunoreactivity was detected in the vascular endothelial cells in mammary glands of wild type adult mice (Fig. 3F), but not in the cells of Id-1 null mutant mice (Fig. 3E, inset).

It is well known that mammary epithelial cells of adult non-pregnant females, for the most part, are mitotically quiescent and proliferate extensively only with the onset of pregnancy [10]. Therefore, to examine whether the lack of expression of Id-1 in the luminal epithelial cells was related to its quiescent state, we also analyzed the tissues from early pregnant females. The patterns of immunostaining in mammary glands did not change either during pregnancy (Fig. 4A), during lactation (Fig. 4B) or during postlactational involution (Fig. 4C). As such, immunoreactivity was still confined to the cytoplasm of the myoepithelial cells and was not detected in luminal epithelial cells. Similar results were also obtained with tissues isolated from the Balb/c strain of mice (data not shown), the strain from which SCp2 cells had been derived [11]. In addition to pregnancy, mammary glands also proliferate extensively at the onset of puberty and, in these glands, the site of intense mitotic activity resides in specialized structures called the terminal end buds [12]. In terminal end buds of pubertal females, immunoreactivity was not detected either in the body cells or the cap cells (Fig. 4D) present at the tips.

Figure 4

Immunohistochemical analyses for Id-1 in mouse mammary glands during various phases of development. Mammary glands from (A) early pregnant, (B) lactating, (C) lactational involuting and (D) pubertal mice were analyzed for the presence of Id-1 as described in the text. Note that, in all the mammary ducts, immunoreactivity is present only in myoepithelial cells and not in the luminal cells. Immunoreactivity is also not detected in the terminal end bud of the pubertal mouse. Original magnification, 400 ×.

In the present report, we have demonstrated that Id-1 is not detectable in the luminal epithelial cells of both mouse and human mammary glands. Our inability to detect Id-1 in these cells is not related to the source of the antibody or techniques since it was possible to detect Id-1 in vascular endothelial cells by immunohistochemistry and via immunoblot analyses of several mouse tissue extracts, including mammary glands. The fact that Id-1 is detected in mammary tissue extracts by immunoblot analyses but not by immunohistochemical analyses therefore indicates that Id-1 detected in whole tissue extracts is derived from non-mammary cells. This argument is supported by our demonstration that Id-1 is expressed in vascular endothelial cells of mammary glands. Furthermore, in contrast to Id-1, we can detect Id-2 in the luminal epithelial cells of mouse mammary glands (N Uehara, Y-C Chou and G Shyamala, unpublished observation) in which Id-2 gene expression has been demonstrated by in situ hybridization [13]. Based on all these observations, we conclude that Id-1 is not expressed in the luminal epithelial cells of mammary glands.

Our studies also demonstrate clearly that in mice, regardless of the strain or the developmental stage, Id-1 is not detectable in the luminal epithelial cells; this included both puberty and early pregnancy, when mammary glands undergo extensive proliferation. Accordingly, our present observations do not support the previous suggestion that, in mammary epithelial cells, Id-1 is a positive and a negative regulator of proliferation and of differentiation, respectively [3]. In turn, the observations also emphasize that the postulated roles for Id-1, using various cell culture models, may not be applicable to all cell types, particularly in vivo [2]. This is exemplified by the fact that much of the information demonstrating various regulatory roles for Id proteins have used fibroblasts and, as shown here, mammary fibroblasts do not express Id-1.

Finally, the detection of 'non-Id-1' immunoreactivity in immunoblot analyses and in myoepithelial cells, with immunohistochemistry, requires comment. It is clearly not due to an abundant nonspecific protein since the immunoreactivity associated with the myoepithelial cells is quite discreet. Indeed, the immunoreactivity associated with the myoepithelial cells is completely abolished by the blocking peptide (Fig. 2). It is also not due to Id-2 or Id-3, since this antibody is specific to an epitope in the carboxy terminus of Id-1 and has no crossreactivity with these proteins [6, 8]. Furthermore, the nonspecific band detected in immunoblots appears to have some specificity for mammary glands since, to date, we have not detected this band in other mouse tissue extracts. Also, the nonspecific band is eliminated upon exposure to the blocking peptide.

Myoepithelial cells express a number of proteins but several of these are also expressed by luminal epithelial cells [14]. As such, very few proteins are expressed exclusively in the myoepithelial cells, the most prominent one being alpha smooth muscle actin [15]. It is, however, unlikely, that the 'non-Id-1' immunoreactivity associated with myoepithelial cells is alpha smooth muscle actin since it has minimal homology to Id-1 and, in particular, to the peptide used for the generation of the antibody. It is therefore most probably due to some other smooth muscle cell-specific protein capable of recognizing the epitope on the Id-1 (C-20) antibody. Identification of this protein can thus lead to establishing another myoepithelial cell-specific marker, which in turn can contribute to our current understanding of the biology of mammary myoepithelial cells.

Acknowledgements

These studies were supported by a grant from NIH (CA 66541) to GS, a grant from State of California Breast Cancer Research program (5Jb-0014) to RDC, and a grant from Breast Cancer Research Foundation to RB. NU was supported by institution training grant DAMD17-00-1-0224. PdC was supported by a fellowship from the Italian American Cancer Foundation.

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.